Wolf Popper LLP Announces Investigation on Behalf of BillionToOne, Inc. Investors

NEW YORK, Nov. 19, 2026 (GLOBE NEWSWIRE) — Wolf Popper LLP is investigating potential claims on behalf of purchasers of BillionToOne, Inc. (BillionToONe) common stock (NASDAQ: BLLN).

BillionToOne provides genetic testing and recently held its initial public offering on November 5 2025 at $60.00 per share.

Before the market opened on November 18, 2026, short seller Fuzzy Panda Research published a report entitled BillionToOne (BLLN) – Undisclosed Fraudulent Billing Allegations; Deductible Capping Scheme Formers Say is “Against the Law;” Dr’s Debunk Oncology Hype. The report alleges multiple issues including BillionToOne hasn’t disclosed Tennessee is investigating the company for Medicaid fraud, BillionToOne bills insurers for tests the pregnant women don’t need, BillionToOne reduces or eliminates deductibles and copays to encourage doctors and patients to use its test, and BillionToOne overpays doctors for blood draws and supplies free phlebotomists who also perform unrelated work. On that news, BillionToOne’s stock price fell $5.96 per share to $91.54, down 6.1% on heavy volume.

Investors who suffered losses trading in BillionToOne common stock and who would like to discuss the investigation should contact Adam Savett at (212) 451-9655, or [email protected].

Wolf Popper has successfully recovered billions of dollars for defrauded investors. Wolf Popper’s reputation and expertise have been repeatedly recognized by courts that have appointed the firm to major positions in securities litigation. For more information about Wolf Popper, please visit the Firm’s website at www.wolfpopper.com.

May Be Considered Attorney Advertising in Certain Jurisdictions.
Prior Results Do Not Guarantee a Similar Outcome.

Wolf Popper LLP
Adam Savett. Esq.
570 Lexington Avenue
New York, NY 10022
Tel.: (212) 451-9655
Email: [email protected]